Physician profile
Abraham Jacob
NPI 1376592576
$20,592.50
in general payments reported to CMS, 2019-2025
9 companies · $11K in 2025
The $11K reported for 2025 was more than what 90% of Otology & Neurotology providers received nationally (typical 2025 total: $411).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,257 · 2020: $900 · 2021: $120 · 2022: $36.89 · 2023: $2,509 · 2024: $5,175 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,150 · Travel and Lodging: $4,349 · Honoraria: $3,600 · Food and Beverage: $3,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,150.00 |
| Travel and Lodging | $4,348.51 |
| Honoraria | $3,600.00 |
| Food and Beverage | $3,179.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cochlear Americas | $10,332.86 | 2019-2025 | Baha, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Osia Osi300 Implant |
| Med-El Corporation | $9,802.47 | 2019-2025 | Bci 602 Kit, Mi1250 Synchrony 2 Flexsoft, Adhear Professional Kit |
| Advanced Bionics, LLC | $198.00 | 2019-2025 | Hires Ultra Ci Hifocus Ms Electrode |
| Oticon Medical, LLC | $120.63 | 2025 | Ponto Bone Anchored Hearing System |
| Acclarent, INC | $80.32 | 2021 | |
| Alexion Pharmaceuticals, INC. | $21.21 | 2024 | Ultomiris |
| Ucb, INC. | $16.03 | 2025 | Rystiggo |
| Lilly USA, LLC | $13.64 | 2023 | Emgality |
| Aucta Pharmaceuticals, INC. | $7.34 | 2025 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abraham Jacob listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.